Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate
may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
Combining interferon alfa with imatinib mesylate may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with imatinib
mesylate in treating patients who have chronic myelogenous leukemia.